Foreign pharmaceutical corporations execute agreements and acquisition to access grassroots markets

On August 24, pharmaceutical giant Pfizer signed a strategic cooperation agreement with Chinese medical distribution company Jointown Pharmaceutical Group to open up sales channels into county-level hospitals. This in turn grants Jointown, Hubei’s largest private enterprise, the distribution rights ...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Japan's METI announces financial support for overseas CCS projects

News Commentary | February 25, 2021

Since Japan announced its carbon neutrality pledge, the Ministry of Economy, Trade and Industry (METI) has launched a product database for CO2‑derived products and will now provide financial support for overseas carbon capture and sequestration (CCS) projects. The focus on non‑Japan CCS projects ... Not part of subscription

BioNTech to set up its regional headquarters and an mRNA vaccine manufacturing facility in Singapore

News Commentary | May 12, 2021

Pfizer's biotech partner that developed the mRNA vaccine against COVID‑19 has moved quickly to ensure it can be elastic in its response to shifting regional and global supply needs for its vaccine given the unpredictable outbreaks in recent times. This move also comes just weeks after Sanofi ... To read more, click here.

Lymphoma patients in Australia can now access CAR T cell therapy

News Commentary | August 06, 2021

The Australian government will now fund the use of Yescarta, a CAR T cell therapy from Gilead/Kite Pharma for the treatment of certain aggressive lymphomas. Yescarta is only the second CAR T cell therapy to have been approved by the FDA after Novartis' Kymriah, as we discuss in our recent insight on... Not part of subscription